The primary purpose of these practical guidelines related to Kawasaki disease (KD) is to contribute to prompt diagnosis and appropriate treatment on the basis of different specialists’ contributions in the field. A set of 40 recommendations is provided, divided in two parts: the first describes the definition of KD, its epidemiology, etiopathogenetic hints, presentation, clinical course and general management, including treatment of the acute phase, through specific 23 recommendations.
Their application is aimed at improving the rate of treatment with intravenous immunoglobulin and the overall potential development of coronary artery abnormalities in KD. Guidelines, however, should not be considered a norm that limits treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient’s condition, and disease severity or complications.
McCrindlle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term Management of Kawasaki Disease, a scientific statement for health professionals from the American heart. Circulation. 2017;135:e927–99. CrossRef
Kawasaki T. Acute febrile mucocutaneus syndrome with lymphoid involvement with specific desquamation of the finger and toes in children. Arerugi. 1967;16:178–222. PubMed
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management in Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young. Am Heart Assoc Pediatrics. 2004;114:1708–33.
Tamburlini G, Strinati R, Cadorini S, Calligaris A, Coprivez A, Cozzi M, et al. A two-year survey of mucocutaneous lymph node syndrome in north-eastern Italy. Epidemiological and clinical findings. Helv Paediatr Acta. 1984;39:319–29. PubMed
Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol. 2011;9:17. CrossRef
De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci. 2007;11:301–8. PubMed
Kang HJ, Kim GN, Kil HR. Changes of clinical characteristics and outcomes in patients with Kawasaki disease over the past 7 years in a single center study. Kor J Pediatr. 2013;56:389–95. CrossRef
Fujita Y, Nakamura Y, Sakata K, Hara N, Kobayashi M, Nagai M, et al. Kawasaki disease in families. Pediatrics. 1989;84:666–9. PubMed
Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Parents with a history of Kawasaki disease whose child also had the same disease. Pediatrics Int. 2011;53:511–4. CrossRef
Kitano N, Suzuki H, Takeuchi T, Suenaga T, Kakimoto N, Shibuta S, et al. Epidemiologic features and prognostic factors of coronary artery lesions associated with Kawasaki disease based on a 13-year cohort of consecutive cases identified by complete enumeration surveys in Wakayama, Japan. J Epidemiol. 2014;24:427–34. PubMedCrossRef
Ma XJ, Yu CY, Huang M, Chen SB, Huang MR, Huang GY. Epidemiologic features of Kawasaki disease in Shanghai from 2003 through 2007. Chin Med J (Engl). 2010;123:2629–34.
Ng YM, Sung RY, So LY, Fong NC, Ho MH, Cheng YW, et al. Kawasaki disease in Hong Kong, 1994 to 2000. Hong Kong Med J. 2005;11:331–5. PubMed
Li XH, Li XJ, Li H, Xu M, Zhou M. Epidemiological study of Kawasaki disease in Sichuan province of China. J Trop Pediatr. 2008;52:133–6.
Durongpisitkul K, Sandtawesin C, Khongphatthanayopthin A, Panamonta M, Sopontammarak S, Sittiwangkul R, et al. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand. Asian Pac J Allergy Immunol. 2006;24:27–32. PubMed
Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease with particular emphasis on arterial lesions. Acta Pathol Jpn. 1991;41:785–973. PubMed
Kuo HC, Chao MC, Hsu YW, Lin YC, Huang YH, Yu HR, et al. CD40 gene polymorphisms associated with susceptibility and coronary artery lesions of Kawasaki disease in the Taiwanese population. Sci World J. 2012;2012:520865. CrossRef
Yoon KL. Update of genetic susceptibility in patients with Kawasaki disease. Kor J Pediatr. 2015;58:84–8. CrossRef
Falcini F, Ozen S, Magni-Manzoni S, Candelli M, Ricci L, Martini G, et al. Discrimination between incomplete and atypical Kawasaki syndrome versus other febrile diseases in childhood: results from an international registry-based study. Clin Exp Rheumatol. 2012;30:799–804. PubMed
Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile arthritis. J Pediatr. 2005;149:598–604. CrossRef
Rigante D. Autoinflammatory syndromes behind the scenes of recurrent fevers in children. Med Sci Monit. 2009;15(8):RA179–87. PubMed
Research Committee on Kawasaki Disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Tokyo: Ministry of Health and Welfare; 1984.
Joint Working Groups: the Japanese Circulation Society, The Japanese Society of Kawasaki Disease, The Japanese Association for Thoracic Surgery, The Japan Pediatric Society, The Japanese Society of Pediatric Cardiology and Cardiac Surgery, The Japanese College of Cardiology. Guidelines for Diagnosis and Management of Cardiovascular Sequelae in Kawasaki disease (JCS 2013). Circ J. 2014;78:2521–62. CrossRef
Ntsinjana HN, Tann O, Hughes M, Derrick G, Secinaro A, Schievano S, et al. Utility of adenosine stress perfusion CMR to assess paediatric coronary artery disease. Eur Heart J Cardiovasc Imaging. 2016; Epub ahead of print
Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003;4:CD004000.
Shamim I. Diagnosis and treatment of suspected Kawasaki disease before the fifth day of illness. Ped Inf Dis J. 2013;32:424.
Nimmerjahan F, Ravetch J. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513–33. CrossRef
Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki Disease. Guidelines for medical treatment of acute Kawasaki disease: Report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). Pediatr Int. 2014;56:135–58. CrossRef
Esposito S, Rigante D, Principi N. The role of infection in Kawasaki syndrome. J Inf Secur. 2013;67:1–10.
Esposito S, Bianchini S, Dellepiane RM, Principi N. Vaccines and Kawasaki disease. Expert Rev Vaccines. 2016;15(3):417–24. PubMed
Heijstek MW, Ott de Bruin LM, Borrow R, van der Klis F, Koné-Paut I, Fasth A, et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev. 2011;11:112–22. PubMedCrossRef
Dell'Era L, Esposito S, Corona F, Principi N. Vaccination of children and adolescents with rheumatic diseases. Rheumatology (Oxford). 2011;50:1358–65. CrossRef
- Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase
Isabella Tarissi de Jacobis
Fabrizio De Benedetti
Andrea De Zorzi
Domenico Del Principe
Rosa Maria Dellepiane
Maya El Hachem
Maria Cristina Maggio
Maria Cristina Pietrogrande
- BioMed Central
Neu im Fachgebiet Pädiatrie
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II